Skip to main content

Prevention Harmful Effects

2
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

EuBiologics
EuBiologicsKorea - Seoul
2 programs
1
1
EuvicholPhase 32 trials
EuvicholPhase 11 trial
Active Trials
NCT01707537Completed20Est. Feb 2013
NCT07509047Recruiting390Est. Dec 2027
NCT02164110Completed3,632Est. Oct 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
EuBiologicsEuvichol
EuBiologicsEuvichol
EuBiologicsEuvichol

Clinical Trials (3)

Total enrollment: 4,042 patients across 3 trials

To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children

Start: May 2014Est. completion: Oct 20143,632 patients
Phase 3Completed

Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children

Start: Jan 2026Est. completion: Dec 2027390 patients
Phase 2Recruiting

To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

Start: Sep 2012Est. completion: Feb 201320 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 4,042 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.